glutamine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	1311	56-85-9

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: L-Glutamine glutamine glutamic acid amide L-(+)-Glutamine L-2-Aminoglutaramidic acid levoglutamide	A non-essential amino acid present abundantly throughout the body and is involved in many metabolic processes. It is synthesized from GLUTAMIC ACID and AMMONIA. It is the principal carrier of NITROGEN in the body and is an important energy source for many cells. Molecular weight: 146.15 Formula: C5H10N2O3 CLOGP: -3.38 LIPINSKI: 0 HAC: 5 HDO: 3 TPSA: 106.41 ALOGS: -0.17 ROTB: 4 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

L-Glutamine
glutamine
glutamic acid amide
L-(+)-Glutamine
L-2-Aminoglutaramidic acid
levoglutamide

A non-essential amino acid present abundantly throughout the body and is involved in many metabolic processes. It is synthesized from GLUTAMIC ACID and AMMONIA. It is the principal carrier of NITROGEN in the body and is an important energy source for many cells.

Molecular weight: 146.15
Formula: C5H10N2O3
CLOGP: -3.38
LIPINSKI: 0
HAC: 5
HDO: 3
TPSA: 106.41
ALOGS: -0.17
ROTB: 4

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

None

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
June 10, 2004	FDA	EMMAUS MEDCL

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Sickle cell anaemia with crisis	73.52	22.39	18	1177	5985	63481842

Showing 1 to 1 of 1 entries

Previous1Next

FDA Adverse Event Reporting System (Male)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Sickle cell anaemia with crisis	149.04	29.71	30	649	4023	34952229
Tendon calcification	52.38	29.71	7	672	68	34956184
Acute chest syndrome	48.03	29.71	9	670	818	34955434
Blood parathyroid hormone increased	31.37	29.71	7	672	1507	34954745

Showing 1 to 4 of 4 entries

Previous1Next

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Sickle cell anaemia with crisis	182.65	21.43	40	1526	7882	79734940
Tendon calcification	47.16	21.43	7	1559	149	79742673
Acute chest syndrome	42.20	21.43	9	1557	1552	79741270
Blood parathyroid hormone increased	25.56	21.43	7	1559	3438	79739384
Tendon rupture	23.95	21.43	9	1557	12117	79730705

Showing 1 to 5 of 5 entries

Previous1Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	A16AA03	ALIMENTARY TRACT AND METABOLISM OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS Amino acids and derivatives
CHEBI has role	CHEBI:27027	trace elements
CHEBI has role	CHEBI:50733	Dietary Supplement
CHEBI has role	CHEBI:61908	nitric oxide synthase inhibitors
CHEBI has role	CHEBI:75771	Mus musculus metabolites
CHEBI has role	CHEBI:75772	S. cerevisiae metabolites
CHEBI has role	CHEBI:76971	Escherichia coli metabolites
CHEBI has role	CHEBI:77746	Homo sapiens metabolite
CHEBI has role	CHEBI:78675	fundamental metabolites
CHEBI has role	CHEBI:25212	metabolites

Showing 1 to 10 of 12 entries

Previous1 2Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Short bowel syndrome	indication	26629001	DOID:10605
Hb SS disease	symptomatic treatment	127040003	DOID:10923

Showing 1 to 2 of 2 entries

Previous1Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	2.17	acidic
pKa2	12.12	acidic
pKa3	9.22	Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

Show entries

Search:

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Exclusivity date	Description
5GM/PACKET	ENDARI	EMMAUS MEDCL	N208587	July 7, 2017	RX	FOR SOLUTION	ORAL	July 7, 2024	TO REDUCE THE ACUTE COMPLICATIONS OF SICKLE CELL DISEASE IN ADULT AND PEDIATRIC PATIENTS 5 YEARS OF AGE AND OLDER.

Showing 1 to 1 of 1 entries

Previous1Next

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Amino acid transporter	Transporter		Q9Z1J7_RAT		IC50	4.57		CHEMBL

Showing 1 to 1 of 1 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
GLN	PDB_CHEM_ID
000928	NDDF
0RH81L854J	UNII
12067	MMSL
1413	INN_ID
158599	MMSL
158601	MMSL
25761002	SNOMEDCT_US
4025874	VANDF
4027901	VUID

Showing 1 to 10 of 22 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Endari	HUMAN PRESCRIPTION DRUG LABEL	1	42457-420	POWDER, FOR SOLUTION	5 g	ORAL	NDA	26 sections
Endari	HUMAN PRESCRIPTION DRUG LABEL	1	42457-420	POWDER, FOR SOLUTION	5 g	ORAL	NDA	26 sections

Showing 1 to 2 of 2 entries

Previous1Next